No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a

BACKGROUND: No evidence of disease activity (NEDA; defined as no 12-week confirmed disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions) using a fixed-study entry baseline is commonly used as a treatment outcome in multiple sclerosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Havrdová, Eva, Arnold, Douglas L, Bar-Or, Amit, Comi, Giancarlo, Hartung, Hans-Peter, Kappos, Ludwig, Lublin, Fred, Selmaj, Krzysztof, Traboulsee, Anthony, Belachew, Shibeshih, Bennett, Iain, Buffels, Regine, Garren, Hideki, Han, Jian, Julian, Laura, Napieralski, Julie, Hauser, Stephen L, Giovannoni, Gavin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858626/
https://www.ncbi.nlm.nih.gov/pubmed/29568544
http://dx.doi.org/10.1177/2055217318760642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858626/
https://www.ncbi.nlm.nih.gov/pubmed/29568544
http://dx.doi.org/10.1177/2055217318760642

Ejemplares similares